• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发和评估用于死后人类阿尔茨海默病大脑 Tau 成像的 [I]IPPI。

Development and evaluation of [ I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain.

机构信息

Preclinical Imaging, Department of Radiological Sciences, University of California, Irvine, CA, USA.

出版信息

Synapse. 2021 Jan;75(1):e22183. doi: 10.1002/syn.22183. Epub 2020 Aug 6.

DOI:10.1002/syn.22183
PMID:32722889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8373522/
Abstract

OBJECTIVE

Alzheimer's disease (AD) is a neurodegenerative disease characterized by aggregation of Tau protein into paired helical filaments causing neurofibrillary tangles (NFT) in the brain. The aim of this study was to develop and evaluate the effectiveness of a novel radioiodinated tracer, 6-[ I]iodo-3-(1H-pyrrolo[2,3-c]pyridine-1-yl)isoquinoline ([ I]IPPI), for binding to Tau protein (Ki = 0.75 nM) in postmortem human brain (AD and cognitively normal (CN).

METHODS

Radiosynthesis of [ I]IPPI was carried out by radioiododestannylation and purified chromatographically. Computational modeling studies of IPPI and MK-6240 binding on Tau fibril were evaluated. In vitro autoradiography studies were carried out with [ H]PIB for Aβ plaques and [ I]IPPI for Tau in AD and CN brains and evaluate drug effects.

RESULTS

[ I]IPPI was produced in >95% purity. Molecular modeling of IPPI revealed binding energies of IPPI (-7.8, -8.1, -8.2, -7.5 Kcal/mol) at the four sites were comparable to MK-6240 (-8.7, -8.5, -8.3, -7.5 Kcal/mol). Ratio of average grey matter (GM) [ I]IPPI in AD versus CN was found to be 7.31 (p = .07) and AD GM/ white matter (WM) = 4.35 (p = .09). Ratio of average GM/WM [ I]IPPI in CN was 1.21. Binding of [ I]IPPI correlated with the presence of Tau, confirmed by anti-Tau Dako A0024. Specifically bound [ I]IPPI to Tau in AD brains was displaced by MK-6240 and IPPI (>90%). Monoamine oxidase inhibitors (MAO) inhibitors deprenyl and clorgyline effected [ I]IPPI binding at >1 µM concentrations.

CONCLUSION

[ I]IPPI exhibited high binding in human AD frontal cortex and anterior cingulate and is a suitable radioiodinated ligand for Tau imaging.

摘要

目的

阿尔茨海默病(AD)是一种神经退行性疾病,其特征是 Tau 蛋白聚集形成成对的螺旋丝,导致大脑中的神经原纤维缠结(NFT)。本研究的目的是开发和评估一种新型放射性碘标记示踪剂 6-[I]碘-3-(1H-吡咯并[2,3-c]吡啶-1-基)异喹啉([I]IPPI),用于与 Tau 蛋白(Ki=0.75 nM)结合的有效性,该蛋白来自死后的人脑(AD 和认知正常(CN)。

方法

通过放射性碘去锡和色谱纯化进行[I]IPPI 的放射合成。评估 IPPI 和 MK-6240 与 Tau 纤维结合的计算建模研究。进行体外放射性自显影研究,用[H]PIB 检测 Aβ 斑块,用[I]IPPI 检测 AD 和 CN 脑中的 Tau,并评估药物作用。

结果

[I]IPPI 以> 95%的纯度生产。IPPI 的分子建模显示,IPPI(-7.8、-8.1、-8.2、-7.5 Kcal/mol)在四个部位的结合能与 MK-6240(-8.7、-8.5、-8.3、-7.5 Kcal/mol)相当。AD 中 AD 与 CN 相比,平均灰质(GM)[I]IPPI 的比值为 7.31(p=0.07),AD GM/白质(WM)= 4.35(p=0.09)。CN 中平均 GM/WM [I]IPPI 的比值为 1.21。[I]IPPI 的结合与 Tau 的存在相关,这一点被 Tau 的抗 Dako A0024 抗体所证实。AD 大脑中特异性结合的[I]IPPI 可被 MK-6240 和 IPPI(>90%)置换。单胺氧化酶抑制剂(MAO)抑制剂 deprenyl 和 clorgyline 在>1 µM 浓度下对[I]IPPI 结合产生影响。

结论

[I]IPPI 在人类 AD 额叶皮层和前扣带回中表现出高结合性,是 Tau 成像的合适放射性碘标记配体。

相似文献

1
Development and evaluation of [ I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain.开发和评估用于死后人类阿尔茨海默病大脑 Tau 成像的 [I]IPPI。
Synapse. 2021 Jan;75(1):e22183. doi: 10.1002/syn.22183. Epub 2020 Aug 6.
2
[I]INFT: Synthesis and Evaluation of a New Imaging Agent for Tau Protein in Post-Mortem Human Alzheimer's Disease Brain.INFT:用于死后人类阿尔茨海默病脑中 Tau 蛋白的新型成像剂的合成与评价。
Molecules. 2023 Jul 31;28(15):5769. doi: 10.3390/molecules28155769.
3
Comparison of Monoamine Oxidase-A, Aβ Plaques, Tau, and Translocator Protein Levels in Postmortem Human Alzheimer's Disease Brain.阿尔茨海默病患者死后大脑中单胺氧化酶-A、Aβ 斑块、tau 蛋白和转位蛋白水平的比较。
Int J Mol Sci. 2023 Jun 28;24(13):10808. doi: 10.3390/ijms241310808.
4
Radioiodinated Tau Imaging Agent III Molecular Modeling, Synthesis, and Evaluation of a New Tau Imaging Agent, [I]ISAS in Post-Mortem Human Alzheimer's Disease Brain.放射性碘标记 Tau 成像剂 III 分子建模、合成与评价新型 Tau 成像剂 [I]ISAS 在人死后阿尔茨海默病脑中的应用。
Molecules. 2024 Jul 13;29(14):3308. doi: 10.3390/molecules29143308.
5
Measurement of Aβ Amyloid Plaques and Tau Protein in Postmortem Human Alzheimer's Disease Brain by Autoradiography Using [F]Flotaza, [I]IBETA, [I]IPPI and Immunohistochemistry Analysis Using QuPath.使用[F]Flotaza、[I]IBETA、[I]IPPI通过放射自显影法测定死后人类阿尔茨海默病大脑中的Aβ淀粉样斑块和tau蛋白,以及使用QuPath进行免疫组织化学分析。
Biomedicines. 2023 Mar 27;11(4):1033. doi: 10.3390/biomedicines11041033.
6
[F]Flotaza for Aβ Plaque Diagnostic Imaging: Evaluation in Postmortem Human Alzheimer's Disease Brain Hippocampus and PET/CT Imaging in 5xFAD Transgenic Mice.氟替拉嗪用于 Aβ 斑块诊断成像:在人阿尔茨海默病大脑海马体的尸检脑组织和 5xFAD 转基因小鼠的 PET/CT 成像中的评估。
Int J Mol Sci. 2024 Jul 18;25(14):7890. doi: 10.3390/ijms25147890.
7
Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins).人类大脑中神经原纤维病变丰富的区域,其具有结合能力的tau蛋白水平会选择性降低,且异常tau异构体(A68蛋白)会积累。
Lab Invest. 1992 Feb;66(2):212-22.
8
Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue.新型 tau PET 示踪剂[F-18]-MK-6240 在人尸检脑组织中的放射自显影验证。
Acta Neuropathol Commun. 2019 Mar 11;7(1):37. doi: 10.1186/s40478-019-0686-6.
9
Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles.阿尔茨海默病患者和老年对照组的脑成像研究,使用 F-MK-6240,一种针对神经纤维缠结的 PET 示踪剂。
J Nucl Med. 2019 Jan;60(1):107-114. doi: 10.2967/jnumed.118.208215. Epub 2018 Jun 7.
10
Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.18F-MK-6240的临床前特征研究,一种用于体内定量检测人类神经原纤维缠结的有前景的正电子发射断层显像(PET)示踪剂
J Nucl Med. 2016 Oct;57(10):1599-1606. doi: 10.2967/jnumed.115.171678. Epub 2016 May 26.

引用本文的文献

1
[I]IPPI for Tau Imaging: Binding Studies in Postmortem Human Alzheimer's Disease Hippocampus-Subiculum and Evaluation of Drug Effects.[I]用于tau成像的IPPI:对死后人类阿尔茨海默病海马-下托的结合研究及药物效果评估。
Synapse. 2025 Jul;79(4):e70024. doi: 10.1002/syn.70024.
2
[F]Mefway: Imaging Serotonin 5HT Receptors in Human Postmortem Alzheimer's and Parkinson's Disease Anterior Cingulate. Potential Applications to Human Positron Emission Tomography Studies.[F]梅夫韦:人类死后阿尔茨海默病和帕金森病前扣带回中5-羟色胺5HT受体的成像。在人类正电子发射断层扫描研究中的潜在应用。
Biomolecules. 2025 Apr 16;15(4):592. doi: 10.3390/biom15040592.
3
Reduction in [F]Nifene Binding, a PET imaging Probe for α4β2* Nicotinic acetylcholinergic receptors in Hippocampus-Subiculum of postmortem human Alzheimer's disease brain.[F]尼非那明结合减少,一种用于死后人类阿尔茨海默病大脑海马-下托中α4β2*烟碱型乙酰胆碱能受体的PET成像探针。
Brain Res. 2025 Jun 15;1857:149600. doi: 10.1016/j.brainres.2025.149600. Epub 2025 Mar 26.
4
Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [I]Radioiodinated DYRK1A Inhibitor.迈向tau蛋白过度磷酸化成像:双重特异性酪氨酸磷酸化调节激酶1A(DYRK1A)是tau蛋白过度磷酸化成像的潜在靶点吗?分子建模评估与放射性碘化DYRK1A抑制剂的合成
Molecules. 2025 Feb 21;30(5):990. doi: 10.3390/molecules30050990.
5
Radioiodinated Tau Imaging Agent III Molecular Modeling, Synthesis, and Evaluation of a New Tau Imaging Agent, [I]ISAS in Post-Mortem Human Alzheimer's Disease Brain.放射性碘标记 Tau 成像剂 III 分子建模、合成与评价新型 Tau 成像剂 [I]ISAS 在人死后阿尔茨海默病脑中的应用。
Molecules. 2024 Jul 13;29(14):3308. doi: 10.3390/molecules29143308.
6
[I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison with Small-Molecule [F]Flotaza and [I]IBETA in Postmortem Human Alzheimer's Disease.[I]依克那单抗:β淀粉样蛋白斑块结合抗体的合成与评估以及与小分子[F]氟他唑和[I]伊贝他在人类阿尔茨海默病尸检中的比较。
Neurol Int. 2024 Apr 8;16(2):419-431. doi: 10.3390/neurolint16020031.
7
Glutamate's Effects on the N-Methyl-D-Aspartate (NMDA) Receptor Ion Channel in Alzheimer's Disease Brain: Challenges for PET Radiotracer Development for Imaging the NMDA Ion Channel.谷氨酸对阿尔茨海默病大脑中 N-甲基-D-天冬氨酸(NMDA)受体离子通道的影响:用于 NMDA 离子通道成像的 PET 示踪剂开发面临的挑战。
Molecules. 2023 Dec 19;29(1):20. doi: 10.3390/molecules29010020.
8
[I]INFT: Synthesis and Evaluation of a New Imaging Agent for Tau Protein in Post-Mortem Human Alzheimer's Disease Brain.INFT:用于死后人类阿尔茨海默病脑中 Tau 蛋白的新型成像剂的合成与评价。
Molecules. 2023 Jul 31;28(15):5769. doi: 10.3390/molecules28155769.
9
Comparison of Monoamine Oxidase-A, Aβ Plaques, Tau, and Translocator Protein Levels in Postmortem Human Alzheimer's Disease Brain.阿尔茨海默病患者死后大脑中单胺氧化酶-A、Aβ 斑块、tau 蛋白和转位蛋白水平的比较。
Int J Mol Sci. 2023 Jun 28;24(13):10808. doi: 10.3390/ijms241310808.
10
Measurement of Aβ Amyloid Plaques and Tau Protein in Postmortem Human Alzheimer's Disease Brain by Autoradiography Using [F]Flotaza, [I]IBETA, [I]IPPI and Immunohistochemistry Analysis Using QuPath.使用[F]Flotaza、[I]IBETA、[I]IPPI通过放射自显影法测定死后人类阿尔茨海默病大脑中的Aβ淀粉样斑块和tau蛋白,以及使用QuPath进行免疫组织化学分析。
Biomedicines. 2023 Mar 27;11(4):1033. doi: 10.3390/biomedicines11041033.

本文引用的文献

1
Structure-Activity Relationships of Radioiodinated 6,5,6-Tricyclic Compounds for the Development of Tau Imaging Probes.用于开发tau成像探针的放射性碘化6,5,6-三环化合物的构效关系
ACS Med Chem Lett. 2020 Jan 9;11(2):120-126. doi: 10.1021/acsmedchemlett.9b00456. eCollection 2020 Feb 13.
2
AD molecular: Imaging tau aggregates with positron emissions tomography.正电子发射断层扫描显示 AD 分子:tau 聚集物。
Prog Mol Biol Transl Sci. 2019;165:107-138. doi: 10.1016/bs.pmbts.2019.07.007. Epub 2019 Aug 20.
3
Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.鉴定 AV-1451 为一种弱的、非选择性的单胺氧化酶抑制剂。
ACS Chem Neurosci. 2019 Aug 21;10(8):3839-3846. doi: 10.1021/acschemneuro.9b00326. Epub 2019 Aug 5.
4
Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.tau PET 示踪剂与单胺氧化酶 B 的交叉相互作用:来自计算机建模和体内成像的证据。
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1369-1382. doi: 10.1007/s00259-019-04305-8. Epub 2019 Mar 27.
5
Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue.新型 tau PET 示踪剂[F-18]-MK-6240 在人尸检脑组织中的放射自显影验证。
Acta Neuropathol Commun. 2019 Mar 11;7(1):37. doi: 10.1186/s40478-019-0686-6.
6
Tau PET imaging in neurodegenerative tauopathies-still a challenge.神经退行性 tau 病中的 tau PET 成像——仍然是一个挑战。
Mol Psychiatry. 2019 Aug;24(8):1112-1134. doi: 10.1038/s41380-018-0342-8. Epub 2019 Jan 11.
7
FDDNP-PET Tau Brain Protein Binding Patterns in Military Personnel with Suspected Chronic Traumatic Encephalopathy1.FDDNP-PET 脑 Tau 蛋白结合模式在疑似慢性创伤性脑病的军事人员中 1。
J Alzheimers Dis. 2018;65(1):79-88. doi: 10.3233/JAD-171152.
8
In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls.在体鉴定和定量研究人类神经纤维缠结 Tau PET 放射性配体 F-MK-6240 从阿尔茨海默病痴呆到年轻对照的变化。
J Nucl Med. 2019 Jan;60(1):93-99. doi: 10.2967/jnumed.118.209650. Epub 2018 May 18.
9
Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling.不同正电子发射断层扫描 Tau 示踪剂与 Tau 纤维上的多个结合位点结合:来自计算建模的见解。
ACS Chem Neurosci. 2018 Jul 18;9(7):1757-1767. doi: 10.1021/acschemneuro.8b00093. Epub 2018 May 2.
10
Tau Filaments and the Development of Positron Emission Tomography Tracers.tau蛋白细丝与正电子发射断层显像剂的研发
Front Neurol. 2018 Feb 15;9:70. doi: 10.3389/fneur.2018.00070. eCollection 2018.